Yusen Chen1, Yun Xiao1, Zhijun Lin1, Xiang Xiao2, Caixia He1, Ji C Bihl3, Bin Zhao1, Xiaotang Ma4, Yanfang Chen5. 1. Department of Neurology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People's Republic of China. 2. Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio. 3. Department of Neurology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People's Republic of China; Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio. 4. Department of Neurology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People's Republic of China. Electronic address: mxtgdmc@163.com. 5. Department of Neurology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People's Republic of China; Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio. Electronic address: yanfang.chen@wright.edu.
Abstract
BACKGROUND: Platelet activation and aggregation are critical in the pathogenesis of acute ischemic stroke (AIS). Circulating platelet microparticles (PMPs) and platelet parameters are biologic markers of platelet function in AIS patients; however, their associations with stroke subtypes and infarct volume remain unknown. METHODS: We recruited 112 AIS patients including large-artery atherosclerosis (LAA) and small-artery occlusion [SAO] subtypes and 35 controls in this study. Blood samples were collected at admission and after antiplatelet therapy. The levels of circulating PMPs and platelet parameters (mean platelet volume [MPV], platelet count, plateletocrit, and platelet distribution width) were determined by flow cytometry and hematology analysis, respectively. Infarct volume was examined at admission by magnetic resonance imaging. RESULTS: (1) The levels of circulating PMPs and MPV were significantly elevated in AIS patients compared with healthy controls; (2) the level of circulating PMPs, but not platelet parameters, was decreased after antiplatelet therapy in AIS patients; (3) the infarct volume in LAA subtype was larger than that in SAO subtype. Notably, circulating PMP level was positively correlated with the infarct volume in LAA subtype. No association with infarct volume in either AIS subtype was observed for platelet parameters; and (4) according to the regression analysis, circulating PMP was an independent risk factor for the infarct volume in pooled AIS patients after adjustments of other impact factors (hypertension and diabetes). CONCLUSIONS: Our results suggest that circulating PMP level is associated with cerebral injury of AIS, which offers a novel evaluation parameter for AIS patients.
BACKGROUND: Platelet activation and aggregation are critical in the pathogenesis of acute ischemic stroke (AIS). Circulating platelet microparticles (PMPs) and platelet parameters are biologic markers of platelet function in AISpatients; however, their associations with stroke subtypes and infarct volume remain unknown. METHODS: We recruited 112 AISpatients including large-artery atherosclerosis (LAA) and small-artery occlusion [SAO] subtypes and 35 controls in this study. Blood samples were collected at admission and after antiplatelet therapy. The levels of circulating PMPs and platelet parameters (mean platelet volume [MPV], platelet count, plateletocrit, and platelet distribution width) were determined by flow cytometry and hematology analysis, respectively. Infarct volume was examined at admission by magnetic resonance imaging. RESULTS: (1) The levels of circulating PMPs and MPV were significantly elevated in AISpatients compared with healthy controls; (2) the level of circulating PMPs, but not platelet parameters, was decreased after antiplatelet therapy in AISpatients; (3) the infarct volume in LAA subtype was larger than that in SAO subtype. Notably, circulating PMP level was positively correlated with the infarct volume in LAA subtype. No association with infarct volume in either AIS subtype was observed for platelet parameters; and (4) according to the regression analysis, circulating PMP was an independent risk factor for the infarct volume in pooled AISpatients after adjustments of other impact factors (hypertension and diabetes). CONCLUSIONS: Our results suggest that circulating PMP level is associated with cerebral injury of AIS, which offers a novel evaluation parameter for AISpatients.
Authors: Elena I Sinauridze; Dmitry A Kireev; Nadezhda Y Popenko; Aleksei V Pichugin; Mikhail A Panteleev; Olga V Krymskaya; Fazoil I Ataullakhanov Journal: Thromb Haemost Date: 2007-03 Impact factor: 5.249
Authors: Albert J Yoo; Zeshan A Chaudhry; Raul G Nogueira; Michael H Lev; Pamela W Schaefer; Lee H Schwamm; Joshua A Hirsch; R Gilberto González Journal: Stroke Date: 2012-03-15 Impact factor: 7.914
Authors: Maria Lukasik; Marcin Rozalski; Boguslawa Luzak; Michal Michalak; Wojciech Ambrosius; Cezary Watala; Wojciech Kozubski Journal: Platelets Date: 2012-02-28 Impact factor: 3.862
Authors: Paul Cherian; Graeme J Hankey; John W Eikelboom; Jim Thom; Ross I Baker; Andrew McQuillan; Janelle Staton; Qilong Yi Journal: Stroke Date: 2003-08-07 Impact factor: 7.914
Authors: Qi Liang; Xin-Jun Lei; Hong-Bing Li; Yang-Rong Yin; Jie Ren; Li-Hong Fan; Xin Huang; Zu-Yi Yuan Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2017-08-20